METTL3 INHIBITOR COMPOUND - SHANGHAI ONCUSP THERAPEUTICS LTD

Title:

METTL3 INHIBITOR COMPOUND

Document Type and Number:

WIPO Patent Application WO/2023/104209

Kind Code:

A1

Abstract:

Provided are a class of METTL3 inhibitor compounds and a use thereof in preparation of a medication for inhibiting METTL3, thereby providing a new option for clinically selecting and/or preparing a medication for a disease related to METTL3 activity.

More Like This:

JP6033317	the -- the substitution tetrahydroisoquinoline compound as XIA factor inhibitor
JP5957016	Primary amine diazenium diolate heterocyclic derivative
JP6876685	Bicyclic compounds as ATX inhibitors

Inventors:

BAI XIAOGUANG (CN)
HONG XINFU (CN)
MARK H NORMAN (US)
ZHAI QINGXI (CN)
ZHOU XIANSI (CN)
ZHANG RUI (CN)
ZHENG ZHIHUI (CN)

Application Number:

PCT/CN2022/138257

Publication Date:

June 15, 2023

Filing Date:

December 11, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SHANGHAI ONCUSP THERAPEUTICS LTD (CN)

International Classes:

C07D401/14; A61K31/437; A61K31/4439; A61P25/00; A61P29/00; A61P31/00; A61P35/00; C07D471/04; C07D487/04; C07D498/04; C07D513/04

Domestic Patent References:

WO2022074379A1	2022-04-14
WO2020201773A1	2020-10-08
WO2021111124A1	2021-06-10

Attorney, Agent or Firm:

GAOYUNG INTELLECTUAL PROPERTY AGENCY (GENERAL PARTNERSHIP) (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: NFC ANTENNA OF HANDHELD DEVICE, AND HANDHELD DEVICE

Next Patent: DATA TRANSMISSION CHIP AND ELECTRONIC DEVICE